

Special Issue

Innovative Approaches in the Management of Sinonasal Cancers

Message from the Guest Editor

Malignancies known as sinonasal cancers develop in the sinonasal area, which includes the paranasal sinuses and nasal cavity. These malignancies can be difficult to treat and frequently necessitate a multidisciplinary approach. So, recently, many improvements have been made in the treatment of sinonasal malignancies, especially in the development of novel strategies. Minimally invasive surgical methods has been one of the most important developments. Moreover, recent developments in diagnostic imaging, including CT scans and MRI helped in precise diagnosis. This has allowed for more individualized treatment plans and better outcomes for patients, such as chemotherapy, radiotherapy, and surgical methods. Furthermore, induction chemotherapy and immunotherapy strategies are being actively investigated for many sinonasal tumor types. In order to encourage continued development in this area, the Special Issue welcomes original research articles and reviews.

Guest Editor

Dr. Niyall London

Sinonasal and Skull Base Tumor Program, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Deadline for manuscript submissions

closed (1 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/166002

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)